SI-Bone (SIBN) to Release Quarterly Earnings on Monday

SI-Bone (NASDAQ:SIBN) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.64) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

SI-Bone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.09). The firm had revenue of $16.82 million during the quarter, compared to analysts’ expectations of $17.98 million. SI-Bone had a negative net margin of 60.51% and a negative return on equity of 51.33%. On average, analysts expect SI-Bone to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-Bone stock opened at $17.10 on Friday. The stock has a 50-day moving average price of $16.39 and a 200 day moving average price of $16.82. SI-Bone has a 52 week low of $7.20 and a 52 week high of $23.10. The company has a current ratio of 7.87, a quick ratio of 7.59 and a debt-to-equity ratio of 0.26.

A number of analysts recently commented on the company. JMP Securities dropped their price objective on SI-Bone from $27.00 to $22.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 5th. Morgan Stanley lifted their price objective on SI-Bone from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of SI-Bone in a research report on Friday, May 29th. Zacks Investment Research upgraded SI-Bone from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Saturday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on SI-Bone in a research report on Monday, June 15th. They set a “buy” rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $22.33.

In other news, insider Anthony J. Recupero sold 3,000 shares of SI-Bone stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $17.49, for a total value of $52,470.00. Following the transaction, the insider now directly owns 76,268 shares of the company’s stock, valued at approximately $1,333,927.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Laura Francis sold 9,971 shares of SI-Bone stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $17.12, for a total value of $170,703.52. Following the completion of the transaction, the chief financial officer now directly owns 141,639 shares in the company, valued at $2,424,859.68. The disclosure for this sale can be found here. Insiders sold a total of 45,024 shares of company stock valued at $804,671 in the last 90 days. 15.50% of the stock is owned by company insiders.

SI-Bone Company Profile

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Featured Story: What is the Shanghai Stock Exchange Composite Index?

Earnings History for SI-Bone (NASDAQ:SIBN)

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.